The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
Open accessAbstract
Nephrotic syndrome is a highly prevalent disease that is associated with high morbidity despite notable advances in its treatment. Many of the complications of nephrotic syndrome, including the increased risk of atherosclerosis and thromboembolism, can be linked to dysregulated lipid metabolism and dyslipidaemia. These abnormalities include elevated plasma levels of cholesterol, triglycerides and the apolipoprotein B-containing lipoproteins VLDL and IDL; decreased lipoprotein lipase activity in the endothelium, muscle and adipose tissues; decreased hepatic lipase activity; and increased levels of the enzyme PCSK9. In addition, there is an increase in the plasma levels of immature HDL particles and reduced cholesterol efflux. Studies from the past few years have markedly improved our understanding of the molecular pathogenesis of nephrotic syndrome-associated dyslipidaemia, and also heightened our awareness of the associated exacerbated risks of cardiovascular complications, progressive kidney disease and thromboembolism. Despite the absence of clear guidelines regarding treatment, various strategies are being increasingly utilized, including statins, bile acid sequestrants, fibrates, nicotinic acid and ezetimibe, as well as lipid apheresis, which seem to also induce partial or complete clinical remission of nephrotic syndrome in a substantial percentage of patients. Future potential treatments will likely also include inhibition of PCSK9 using recently-developed anti-PCSK9 monoclonal antibodies and small inhibitory RNAs, as well as targeting newly identified molecular regulators of lipid metabolism that are dysregulated in nephrotic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
M-Type Phospholipase A 2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy
Beck, L. H., Bonegio, R. G. B., Lambeau, G., Beck, D. M., Powell, D. W., Cummins, T. D., Klein, J. B., & Salant, D. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810457 · Cited by 2,347
Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans
Genovese, G., Friedman, D. J., Ross, M. D., Lecordier, L., Uzureau, P., Freedman, B. I., Bowden, D. W., Langefeld, C. D., Oleksyk, T. K., Uscinski Knob, A. L., et al. (2010) · Science · doi:10.1126/science.1193032 · Cited by 2,028
Keith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B., & Smith, D. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.659 · Cited by 1,684
A Light and Electron Microscopic Study
Schochet, S. S., McCermick, W. F., & F, G. F. (1976) · Cited by 1,642
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
LIPID NEPHROTOXICITY IN CHRONIC PROGRESSIVE GLOMERULAR AND TUBULO-INTERSTITIAL DISEASE
Moorhead, J. F., El-Nahas, M., Chan, M. K., & Varghese, Z. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91513-6 · Cited by 1,070
APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy
Kopp, J. B., Nelson, G. W., Sampath, K., Johnson, R. C., Genovese, G., An, P., Friedman, D., Briggs, W., Dart, R., Korbet, S., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040388 · Cited by 855
Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency
Culleton, B. F., Larson, M. G., Wilson, P. W. F., Evans, J. C., Parfrey, P. S., & Levy, D. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00773.x · Cited by 838
Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease
Tsimikas, S., Brilakis, E. S., Miller, E. R., McConnell, J. P., Lennon, R. J., Kornman, K. S., Witztum, J. L., & Berger, P. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043175 · Cited by 784
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Yuhanna, I. S., Zhu, Y., Cox, B. E., Hahner, L. D., Osborne-Lawrence, S., Lu, P., Marcel, Y. L., Anderson, R. G. W., Mendelsohn, M. E., Hobbs, H. H., et al. (2001) · Nature Medicine · doi:10.1038/89986 · Cited by 742
Mayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., et al. (1997) · Transplantation · doi:10.1097/00007890-199708150-00012 · Cited by 724
Role of HDL, ABCA1, and ABCG1 Transporters in Cholesterol Efflux and Immune Responses
Yvan-Charvet, L., Wang, N., & Tall, A. R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179283 · Cited by 680
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
Vaziri, N. D. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00099.2005 · Cited by 538
Merkel, M., Eckel, R. H., & Goldberg, I. J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200015-jlr200 · Cited by 522
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Podrez, E. A., Byzova, T. V., Febbraio, M., Salomon, R. G., Ma, Y., Valiyaveettil, M., Poliakov, E., Sun, M., Finton, P. J., Curtis, B. R., et al. (2007) · Nature Medicine · doi:10.1038/nm1626 · Cited by 513
High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response
Murphy, A. J., Woollard, K. J., Hoang, A., Mukhamedova, N., Stirzaker, R. A., McCormick, S. P. A., Remaley, A. T., Sviridov, D., & Chin-Dusting, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.168690 · Cited by 508
Kamanna, V. S., & Kashyap, M. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.029 · Cited by 453
Macfarlane, D. P., Forbes, S., & Walker, B. R. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0054 · Cited by 385
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., & Bibbins-Domingo, K. (2016) · JAMA · doi:10.1001/jama.2016.11004 · Cited by 382
Epidemiology and Pathophysiology of Nephrotic Syndrome–Associated Thromboembolic Disease
Kerlin, B. A., Ayoob, R., & Smoyer, W. E. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10131011 · Cited by 379
Self-citationVincenti, F., Jensik, S. C., Filo, R. S., Miller, J., & Pirsch, J. (2002) · Transplantation · doi:10.1097/00007890-200203150-00021 · Cited by 375
Sukonina, V., Lookene, A., Olivecrona, T., & Olivecrona, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604026103 · Cited by 360
GPIHBP1 Is Responsible for the Entry of Lipoprotein Lipase into Capillaries
Davies, B. S. J., Beigneux, A. P., Barnes, R. H., Tu, Y., Gin, P., Weinstein, M. M., Nobumori, C., Nyrén, R., Goldberg, I., Olivecrona, G., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.016 · Cited by 342
Cardioprotective functions of HDLs
Rye, K.-A., & Barter, P. J. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r039297 · Cited by 299
The increased risk of coronary heart disease associated with nephrotic syndrome
Ordoñez, J. D., Hiatt, R. A., Killebrew, E. J., & Fireman, B. H. (1993) · Kidney International · doi:10.1038/ki.1993.292 · Cited by 296
Abnormalities of Lipoprotein Metabolism in Patients with the Nephrotic Syndrome
Joven, J., Villabona, C., Vilella, E., Masana, L., Albertí, R., & Vallés, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230905 · Cited by 292
Ezetimibe therapy: mechanism of action and clinical update
Toth, P., Phan, & Dayspring, T. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 288
Hyperlipidemia in patients with chronic renal disease
Kasiske, B. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820472 · Cited by 281
The Apolipoprotein L1 (APOL1) Gene and Nondiabetic Nephropathy in African Americans
Freedman, B. I., Kopp, J. B., Langefeld, C. D., Genovese, G., Friedman, D. J., Nelson, G. W., Winkler, C. A., Bowden, D. W., & Pollak, M. R. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010070730 · Cited by 271
Tardif, J.-C., Grégoire, J., L’Allier, P. L., Anderson, T. J., Bertrand, O., Reeves, F., Title, L. M., Alfonso, F., Schampaert, E., Hassan, A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000147777.12010.ef · Cited by 252
Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences
Vaziri, N. D. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.026 · Cited by 249
Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage
Kamijo, A., Kimura, K., Sugaya, T., Yamanouchi, M., Hase, H., Kaneko, T., Hirata, Y., Goto, A., Fujita, T., & Omata, M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00618.x · Cited by 213
Keane, W. F. (1994) · Kidney International · doi:10.1038/ki.1994.349 · Cited by 209
Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency
Lovric, S., Goncalves, S., Gee, H. Y., Oskouian, B., Srinivas, H., Choi, W.-I., Shril, S., Ashraf, S., Tan, W., Rao, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89626 · Cited by 205
Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids
Sieber, J., Lindenmeyer, M. T., Kampe, K., Campbell, K. N., Cohen, C. D., Hopfer, H., Mundel, P., & Jehle, A. W. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00196.2010 · Cited by 203
ANTIGLUCOCORTICOID ACTIONS OF DEHYDROEPIANDROSTERONE AND LOW CONCENTRATIONS IN ALZHEIMER'S DISEASE
Svec, F., & Lopez-S, A. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91940-5 · Cited by 192
Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury
Pedigo, C. E., Ducasa, G. M., Leclercq, F., Sloan, A., Mitrofanova, A., Hashmi, T., Molina-David, J., Ge, M., Lassenius, M. I., Forsblom, C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85939 · Cited by 190
Self-citationCirculating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome
Clement, L. C., Macé, C., Avila-Casado, C., Joles, J. A., Kersten, S., & Chugh, S. S. (2014) · Nature Medicine · doi:10.1038/nm.3396 · Cited by 173
HDL abnormalities in nephrotic syndrome and chronic kidney disease
Vaziri, N. D. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.180 · Cited by 166
Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome
Wanner, C., Rader, D. J., Bartens, W., Kramer, J., Brewer, H. B., Schollmeyer, P., & Wieland, H. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00002 · Cited by 146
The pathology of Tangier disease. A light and electron microscopic study.
Ferrans, V. J., & Fredrickson, D. S. (1975) · PubMed Central · Cited by 140
The Nephrotic Syndrome and Its Complications
Cameron, J. S. (1987) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(87)80170-1 · Cited by 139
Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria
Thomas, M. E., Harris, K. P. G., Walls, J., Furness, P. N., & Brunskill, N. J. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00001.2002 · Cited by 137
Eddy, A. A., McCulloch, L. M., Liu, E., & Adams, J. (1991) · PubMed Central · Cited by 130
Birjmohun, R. S., van Leuven, S. I., Levels, J. H. M., Veer, C. V. ′., Kuivenhoven, J. A., Meijers, J. C. M., Levi, M. M., Kastelein, J. J. P., van der Poll, T., & Stroes, E. S. G. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.106.136325 · Cited by 127
Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome
D’Amico, G., Gentile, M. G., Manna, G. M., Fellin, G., Ciceri, R., Cofano, F., Petrini, C., Lavarda, F., Perolini, S., & Porrini, M. (1992) · The Lancet · doi:10.1016/0140-6736(92)90731-h · Cited by 122
Lipid biology of the podocyte—new perspectives offer new opportunities
Fornoni, A., Merscher, S., & Kopp, J. B. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.87 · Cited by 120
Self-citationAKI in Children Hospitalized with Nephrotic Syndrome
Rheault, M. N., Zhang, L., Selewski, D. T., Kallash, M., Tran, C. L., Seamon, M. L., Katsoufis, C. P., Ashoor, I. F., Hernandez, J. D., Supe‐Markovina, K., et al. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06620615 · Cited by 117
Self-citationHaas, M. E., Levenson, A. E., Sun, X., Liao, W.-H., Rutkowski, J. M., Nephrotic Syndrome Study Network, de Ferranti, S. D., Schumacher, V., Scherer, P. E., Salant, D. J., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.020912 · Cited by 117
Lipid profiles in patients with systemic lupus erythematosus.
Leong, K. H., Koh, E. T., Ph, F., & Boey, M. L. (1994) · PubMed · Cited by 113
Gherardi, E., Rota, E., Calandra, S., GENOVA, R., & Tamborino, A. M. (1977) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1977.tb01652.x · Cited by 113
Childhood nephrotic syndrome—current and future therapies
Greenbaum, L. A., Benndorf, R., & Smoyer, W. E. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.115 · Cited by 109
Self-citationCellular Mechanisms of Lipid Injury in the Glomerulus
Schlöndorff, D. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70171-3 · Cited by 107
Extrarenal Complications of the Nephrotic Syndrome
Harris, R. C., & Ismail, N. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80369-6 · Cited by 106
Martínez-García, C., Izquierdo‐Lahuerta, A., Vivas, Y., Velasco, I., Yeo, T.-K., Chen, S., & Medina‐Gómez, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142291 · Cited by 104
Lipid Nephrotoxicity: New Concept for an Old Disease
Gyebi, L. K., Soltani, Z., & Reisin, E. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0250-2 · Cited by 101
Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a)
Sharma, M., Redpath, G. M., Williams, M. J. A., & McCormick, S. P. A. (2017) · Circulation Research · doi:10.1161/circresaha.116.310272 · Cited by 97
Thomas, M. E., Harris, K. P. G., Ramaswamy, C., Hattersley, J., Wheeler, D. C., Varghese, Z., Williams, J. D., Walls, J., & Moorhead, J. F. (1993) · Kidney International · doi:10.1038/ki.1993.358 · Cited by 95
MacGregor, A. J., Dhillon, V. B., Binder, A. I., Forte, C. A., Knight, B. C., Betteridge, D. J., & Isenberg, D. A. (1992) · Annals of the Rheumatic Diseases · doi:10.1136/ard.51.2.152 · Cited by 95
der Velden, M. G. M. D. S., Kaysen, G. A., Barrett, H. A., Stellaard, F., Gadellaa, M. M., Voorbij, H. A. M., Reijngoud, D., & Rabelink, T. J. (1998) · Kidney International · doi:10.1111/j.1523-1755.1998.00831.x · Cited by 92
Venous thromboembolism in pediatric nephrotic syndrome
Kerlin, B. A., Haworth, K. B., & Smoyer, W. E. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2525-5 · Cited by 92
Self-citationMoriarty, P. M., Varvel, S. A., Gordts, P. L. S. M., McConnell, J. P., & Tsimikas, S. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.308704 · Cited by 89
Angiopoietin-like Protein 4 Inhibition of Lipoprotein Lipase
Lafferty, M. J., Bradford, K. C., Erie, D. A., & Neher, S. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497602 · Cited by 88
Rabelink, T. J., Erkelens, D. W., Hené, R. J., Joles, J. A., & Koomans, H. A. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90870-7 · Cited by 87
Albumin-associated free fatty acids induce macropinocytosis in podocytes
Chung, J.-J., Huber, T. B., Gödel, M., Jarad, G., Hartleben, B., Kwoh, C., Keil, A., Karpitskiy, A., Hu, J., Huh, C. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79641 · Cited by 85
Lipoprotein X Causes Renal Disease in LCAT Deficiency
Ossoli, A., Neufeld, E. B., Thacker, S. G., Vaisman, B. L., Pryor, M., Freeman, L. A., Brantner, C. A., Baranova, I. N., Francone, N. O., Demosky, S. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150083 · Cited by 85
Hattori, M., Chikamoto, H., Akioka, Y., Nakakura, H., Ogino, D., Matsunaga, A., Fukazawa, A., Miyakawa, S., Khono, M., Kawaguchi, H., et al. (2003) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.08.012 · Cited by 79
Faraggiana, T., & Churg, J. (1987) · Human Pathology · doi:10.1016/s0046-8177(87)80238-1 · Cited by 79
Effect of lipoproteins on mesangial cell proliferation
Nishida, Y., Oda, H., & Yorioka, N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07113.x · Cited by 76
Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis
Vaziri, N. D., & Liang, K. H. (1995) · Kidney International · doi:10.1038/ki.1995.500 · Cited by 76
Catabolism of very low density lipoproteins in experimental nephrosis.
Garber, D. W., Gottlieb, B. A., Marsh, J. B., & Sparks, C. E. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111548 · Cited by 75
Shearer, G. C., Stevenson, F. T., Atkinson, D. N., Jones, H. B., Staprãns, I., & Kaysen, G. A. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00478.x · Cited by 74
Choi, H. K., & Seeger, J. D. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21329 · Cited by 74
Iwai, T., Kume, S., Chin‒Kanasaki, M., Kuwagata, S., Araki, H., Takeda, N., Sugaya, T., Uzu, T., Maegawa, H., & Araki, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111868 · Cited by 74
Ruggiero, C., Elks, C. M., Kruger, C., Cleland, E., Addison, K., Noland, R. C., & Stadler, K. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00484.2013 · Cited by 73
Liu, S., & Vaziri, N. D. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft439 · Cited by 72
Lipid–Protein Interactions along the Slit Diaphragm of Podocytes
Schermer, B., & Benzing, T. R. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070694 · Cited by 71
Intrarenal renin-angiotensin system mediates fatty acid-induced ER stress in the kidney
Li, C., Lin, Y., Luo, R., Chen, S., Wang, F., Zheng, P., Levi, M., Yang, T., & Wang, W. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00223.2015 · Cited by 71
Lipoprotein distribution and composition in the human nephrotic syndrom
Muls, E., Rosseneu, M., Daneels, R. F., Schurgers, M., & Boelaert, J. R. (1985) · Atherosclerosis · doi:10.1016/0021-9150(85)90181-9 · Cited by 70
PCSK9 in chronic kidney disease
Pavlakou, P., Liberopoulos, E. N., Dounousi, E. C., & Elisaf, M. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1505-2 · Cited by 70
Lipid and apolipoprotein levels in patients with nephrotic syndrome
Takao, O., & Ichito, M. (1981) · Clinica Chimica Acta · doi:10.1016/0009-8981(81)90034-6 · Cited by 64
Nephrotic Syndrome: Components, Connections, and Angiopoietin-Like 4–Related Therapeutics
Macé, C., & Chugh, S. S. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014030267 · Cited by 63
Vaziri, N. D., Yuan, J. J., Ni, Z., Nicholas, S. B., & Norris, K. C. (2011) · Clinical and Experimental Nephrology · doi:10.1007/s10157-011-0549-3 · Cited by 63
Brunzell, J. D., Zambon, A., & Deeb, S. S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.008 · Cited by 62
Sanjad, S. A., Al-Abbad, A., & Al-Shorafa, S. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70213-0 · Cited by 58
Kampe, K., Sieber, J., Orellana, J. M., Mundel, P. H., & Jehle, A. W. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00454.2013 · Cited by 57
Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome
Muso, E., for the Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group, Mune, M., Fujii, Y., Imai, E., Ueda, N., Hatta, K., Imada, A., Miki, S., Kuwahara, T., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07130.x · Cited by 55
Cellular cholesterol efflux to serum is impaired in diabetic nephropathy
Zhou, H., Tan, K. C. B., Shiu, S. W. M., & Wong, Y. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.895 · Cited by 55
Albumin-induced podocyte injury and protection are associated with regulation of COX-2
Agrawal, S., Guess, A. J., Chanley, M. A., & Smoyer, W. E. (2014) · Kidney International · doi:10.1038/ki.2014.196 · Cited by 55
Self-citationApolipoprotein CII and lipoprotein lipase in human nephrotic syndrome
Kashyap, M. L., Srivastava, L., Hynd, B. A., Brady, D., Perisutti, G., Glueck, C. J., & Gartside, P. S. (1980) · Atherosclerosis · doi:10.1016/0021-9150(80)90025-8 · Cited by 53
Simvastatin in nephrotic syndrome
Olbricht, C. J., for the Simvastatin In Nephrotic Syndrome Study Group, Wanner, C., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07128.x · Cited by 53
Gheith, O. A. A., Sobh, M. A. K., Mohamed, K. E.-S., El-Baz, M. A., El-Husseini, F., Gazarin, S. S., Ahmed, H. A.-E.-H., Rasem, M. W., & Amer, G. M. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000065021 · Cited by 53
Treatment of proteinuric patients with a vegetarian soy diet and fish oil.
Gentile, M. G., Fellin, G., Cofano, F., Fave, A. D., Manna, G. M., Ciceri, R., Petrini, C., Lavarda, F., Pozzi, F., & D’Amico, G. (1993) · PubMed · Cited by 52
Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood
Coleman, J. E., & Watson, A. R. (1996) · Pediatric Nephrology · doi:10.1007/bf00862065 · Cited by 51
Treatment of the Hyperlipidemia of the Nephrotic Syndrome: A Controlled Trial
Valeri, A. M., Gelfand, J. L., Blum, C. B., & Appel, G. B. (1986) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(86)80164-0 · Cited by 50
Mobility of “HSPG-bound” LPL explains how LPL is able to reach GPIHBP1 on capillaries
Allan, C. M., Larsson, M., Jung, R. S., Ploug, M., Bensadoun, A., Beigneux, A. P., Fong, L. G., & Young, S. G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m072520 · Cited by 48
Lipid-lowering agents for nephrotic syndrome
Kong, X., Yuan, H., Fan, J., Li, Z., Wu, T., & Jiang, L. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005425.pub2 · Cited by 46
Beneficial effect of LDL-apheresis in refractory nephrotic syndrome
Muso, E. (2014) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0930-5 · Cited by 45
Treatment of nephrotic hyperlipoproteinemia with gemfibrozil
Groggel, G. C., Cheung, A. K., Ellis-Benigni, K., & Wilson, D. E. (1989) · Kidney International · doi:10.1038/ki.1989.189 · Cited by 45
Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats
Zhou, Y., Zhang, X., Chen, L., Wu, J., Dang, H., Wei, M., Fan, Y., Zhang, Y., Zhu, Y., Wang, N., et al. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00046.2008 · Cited by 45
High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria
Tentolouris, N., Stylianou, A., Lourida, E. S., Perrea, D. N., Kyriaki, D., Papavasiliou, E. C., Tselepis, A. D., & Katsilambros, N. L. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600367-jlr200 · Cited by 42
Vaziri, N. D., & Liang, K. H. (2004) · Circulation · doi:10.1161/01.cir.0000136023.70841.0f · Cited by 42
Current concepts of the podocyte in nephrotic syndrome
Ding, W. Y., & Saleem, M. A. (2012) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2012.04.323 · Cited by 39
The clot thickens—oxidized lipids and thrombosis
Jackson, S. P., & Calkin, A. C. (2007) · Nature Medicine · doi:10.1038/nm0907-1015 · Cited by 35
Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia
Gheith, O. A. A., Sheashaa, H., Abdelsalam, M. A. M., Shoeir, Z., & Sobh, M. A. K. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0033-x · Cited by 35
The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome
Büyükçelik, M., Anarat, A., Bayazıt, A. K., et al. (2002) · The Turkish Journal of Pediatrics · doi:10.24953/turkjpediatr.2002.2935 · Cited by 32
Awanami, Y., Fukuda, M., Nonaka, Y., Takashima, T., Matsumoto, K., Yamasaki, M., Miyazono, M., & Ikeda, Y. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0644-0 · Cited by 26
Omega-3 fatty acid supplementation in primary nephrotic syndrome
Hall, A. V., Parbtani, A., Clark, W. F., Spanner, E., Huff, M. W., Philbrick, D. J., & Holub, B. J. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v361321 · Cited by 25
Yeang, C., Gordts, P. L. S. M., & Tsimikas, S. (2017) · Circulation Research · doi:10.1161/circresaha.117.310700 · Cited by 25
Zuo, N., Zheng, X., Liu, H., & Ma, X. (2015) · PubMed · Cited by 24
Stevenson, F. T., Shearer, G. C., & Atkinson, D. N. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00720.x · Cited by 21
Zhong, S., Zhao, L., Li, Q., Yang, P., Varghese, Z., Moorhead, J. F., Chen, Y., & Ruan, X. Z. (2014) · Inflammation · doi:10.1007/s10753-014-0058-0 · Cited by 19
PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook
Bartolo, B. A. D., Scherer, D. J., Brown, A. D. H., Psaltis, P. J., & Nicholls, S. J. (2017) · BioDrugs · doi:10.1007/s40259-017-0220-y · Cited by 18
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Kopp, J. B., Anders, H.-J., Susztak, K., Podestà, M. A., Remuzzi, G., Hildebrandt, F., & Romagnani, P. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0196-7 · Cited by 562
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
on behalf of the International Pediatric Nephrology Association, Trautmann, A., Vivarelli, M., Samuel, S., Gipson, D., Sinha, A., Schaefer, F., Hui, N. K., Boyer, O., Saleem, M. A., et al. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04519-1 · Cited by 389
Self-citationOkamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Metadata
- Authors
- Agrawal, S., Zaritsky, J. J., Fornoni, A., & Smoyer, W. E.
- Venue
- Nature Reviews Nephrology
- Published
- 2017-11-27
- Volume
- 14
- Issue
- 1
- Pages
- 57-70
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- OpenAlex
- W2770674556
- Cited by
- 325
- References
- 122
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.